HeadWise HeadWise: Volume 6, Issue 3 | Page 10

DON’T LIE DOWN
STAND UP
TO CHRONIC MIGRAINE
For adults with Chronic Migraine
For adults with Chronic Migraine,
15 or more headache days a month,
each lasting 4 hours or more BOTOX® is the fi rst and only
FDA-approved preventive treatment
for Chronic Migraine
BOTOX® prevents on average 8 to 9 headache days and migraine/
probable migraine days a month (versus 6 to 7 for placebo). BOTOX®
is not approved for adults with migraine who have 14 or fewer
headache days a month. ● BOTOX® is proven to prevent headaches before they even start
● BOTOX® is shown to prevent migraines before they even start
● BOTOX® is injected by a doctor once every 12 weeks
● BOTOX® is covered by most insurance companies
Talk to a headache specialist
Go online for more information and to learn about savings
BOTOXChronicMigraine.com
INDICATION
BOTOX® is a prescription medicine that is injected to prevent headaches in adults with chronic migraine who have 15 or more days each month with
headache lasting 4 or more hours each day in people 18 years or older.
It is not known whether BOTOX® is safe or eff ective to prevent headaches in patients with migraine who have 14 or fewer headache days each month
(episodic migraine).
IMPORTANT SAFETY INFORMATION
BOTOX® may cause serious side eff ects that can be life threatening.
Get medical help right away if you have any of these problems any
time (hours to weeks) a� er injection of BOTOX®:
● Problems swallowing, speaking, or breathing, due to weakening of
associated muscles, can be severe and result in loss of life. You are at
the highest risk if these problems are pre-existing before injection.
Swallowing problems may last for several months.
● Spread of toxin eff ects. The eff ect of botulinum toxin may aff ect
areas away from the injection site and cause serious symptoms
including: loss of strength and all-over muscle weakness, double
vision, blurred vision and drooping eyelids, hoarseness or change or
loss of voice, trouble saying words clearly, loss of bladder control,
trouble breathing, trouble swallowing.
Please see additional Important Safety Information on adjacent page.
© 2016 Allergan, Inc., Irvine, CA 92612. ® marks owned by Allergan, Inc. Dysport is a registered trademark of Ipsen Biopharm Limited Company. Myobloc is a registered trademark of Solstice Neurosciences, Inc. Xeomin is a registered trademark of Merz Pharma GmbH & Co KGaA. APC24HN16
10
HeadW ise ®
|
Volume 6, Issue 3 • 2017